as on October 25, 2025 at 1:29 am IST
Day's Low
Day's High
0.52%
Downside
0.18%
Upside
52 Week's Low
52 Week's High
65.02%
Downside
0.18%
Upside
Check Merus Nv market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$7.2B
EPS (TTM)
-5.6038
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-344.5M
Revenue (TTM)
56.2M
Profit Margin
0.00%
Return On Equity TTM
-48.54%
Compare market cap, revenue, PE, and other key metrics of Merus Nv with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $7.2B | 626.49% | NA | 0.00% | |
| BUY | $60.9B | 251.51% | -505.15 | -12.96% | |
| NA | $35.7B | NA | NA | -3.89% | |
| BUY | $109.3B | 99.16% | 30.04 | 31.86% | |
| BUY | $62.0B | -0.32% | 14.51 | 31.37% |
The Merus Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Merus Nv investment value today
Current value as on today
₹1,83,397
Returns
₹83,397
(+83.4%)
Returns from Merus Nv Stock
₹78,835 (+78.84%)
Dollar Returns*
₹4,562 (+4.56%)
Based on 20 analysts
95.00%
Buy
5.00%
Hold
0.00%
Sell
Based on 20 analysts, 95% of analysts recommend a 'BUY' rating for Merus Nv. Average target price of $97
Get share price movements and forecasts by analysts on Merus Nv.
What analysts predicted
2.18%UPSIDE
Target Price
$97
Current Price
$94.89
Analyzed by
20 Analysts
Target
$97.00
Merus Nv target price $97, a slight upside of 2.18% compared to current price of $94.89. According to 20 analysts rating.
Search interest for Merus Nv Stock has increased by 356% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:356% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 29 September
Mon, 05:02 PM
-Genmab expects to finalize the Merus acquisition in Q1 2026, enhancing its drug pipeline.
Mon, 07:16 PM
-Citi downgraded Merus to Neutral after Genmab's acquisition announcement, with a price target of $97.
Mon, 07:45 PM
-Genmab's acquisition of Merus valued at $97 per share, a 41% premium over previous closing price.
Today's Timeline - 29 September
Mon, 09:18 PM
-Merus shares surged 36% after Genmab agreed to acquire the company for $8 billion, or $97 per share.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Best in 3 Years
![]()
In the last 3 years, MRUS has outperformed top 5 stocks with highest market-cap in its industry
Price Rise
![]()
In the last 1 month, MRUS stock has moved up by 39.3%
Best in 1 Year
![]()
In the last 1 year, MRUS has outperformed top 5 stocks with highest market-cap in its industry
Profit Down
![]()
Netprofit is down for the last 3 quarters, -30.92M → -134.32M (in $), with an average decrease of 119.5% per quarter
Revenue Fall
![]()
Revenue is down for the last 2 quarters, 24.48M → 7.49M (in $), with an average decrease of 69.4% per quarter
| Organisation | Merus Nv |
| Headquarters | Uppsalalaan 17, Utrecht, Netherlands, 3584 CT |
| Industry | Health Technology |
| CEO | Dr. Sven Ante Lundberg M.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Sven Ante Lundberg M.D. | CEO, President & Executive Director |
Mr. Peter B. Silverman J.D. | EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal |
Dr. Fabian Zohren M.D., Ph.D. | Chief Medical Officer |
Mr. Cornelis Adriaan de Kruif Ph.D. | CTO & Executive VP |
Ms. Kathleen Farren | Director of IR & Corporate Communications Officer |
Mr. Gregory D. Perry | Chief Financial Officer |
Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor |
Mr. Harry Shuman | Chief Accounting Officer |
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer & Senior VP |
Ms. Sherri Spear | Senior Vice President of Investor Relations & Strategic Communications |
Merus Nv share price today is $94.89 as on at the close of the market. Merus Nv share today touched a day high of $95.06 and a low of $94.4.
Merus Nv share touched a 52 week high of $95.06 on and a 52 week low of $33.19 on . Merus Nv stock price today i.e. is closed at $94.89,which is 0.18% down from its 52 week high and 185.90% up from its 52 week low.
Merus Nv market capitalisation is $0.01T as on .
Indian investors can start investing in Merus Nv (MRUS) shares with as little as ₹87.759 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹877.59 in Merus Nv stock (as per the Rupee-Dollar exchange rate as on ).
Based on Merus Nv share’s latest price of $94.89 as on October 25, 2025 at 1:29 am IST, you will get 0.1054 shares of Merus Nv. Learn more about
fractional shares .
Merus Nv stock has given 626.49% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?